Breast Cancer

, 4:93 | Cite as

Meta-analysis of the second collaborative study of adjuvant chemoendocrine therapy for breast cancer (acetbc) in patients with stage ii, estrogen-receptor-positive breast cancer

  • Minoru Yoshida
  • Osahiko Abe
  • Junichi Uchino
  • Kaneo Kikuchi
  • Rikiya Abe
  • Kohji Enomoto
  • Takeshi Tominaga
  • Atsuo Fukami
  • Keizo Sugimachi
  • Yasuo Nomura
  • Takao Hattori
  • Nobuya Ogawa
Article
Received:
Accepted:

Abstract

The second 5-year study of postoperative adjuvant therapy in patients with breast cancer between 1985 and 1988 was performed by the Study Group for Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC). This report describes the results of a meta-analysis of the outcome. A total of 3012 patients with stage II, estrogen-receptor-positive primary breast cancer who underwent radical surgery (total mastectomy with at least axillary dissection) were eligible for the analyses. On the day of surgery, all patients received 13 mg/m2 of mitomycin C (MMC) intravenously. Patients were then given one of two adjuvant chemoendocrine therapies for 2 years: regimen A, consisting of tamoxifen citrate (TAM) 30 mg/day, or regimen B, consisting of TAM 30 mg/day plus tegafur (Futraful, FT) 600 mg/day. The results from all eligible patients were included in a meta-analysis according to the method of Petoet al. The odds reduction rate was 12 ± 13% (log-rank test,p = 0.35) for the 5-year survival rate and 16±10% (log-rank test, p = 0.093) for the 5-year non-recurrence rate. In terms of the 5-year non-recurrence rate, regimen B (with FT) yielded slightly, but not significantly, better results than regimen A. In addition, stratified analyses were carried out with respect to the 5-year non-recurrence rate. Regimen B (with FT) yielded significantly better results than regimen A in patients with four or more positive axillary nodes (log-rank test,p = 0.039) and yielded slightly, but not significantly, better results than regimen A in premenopausal patients (log-rank test,p = 0.079).

Key words

Meta-analysis Postoperative adjuvant chemoendocrine therapy Breast cancer Tegafur (Futraful) Tamoxifen citrate 

Abbreviations

ACETBC

Adjuvant chemoendocrine therapy for breast cancer

ER

Estrogen receptor

MMC

Mitomycin C

TAM

Tamoxifen citrate

FT

Futraful

CMF

Cyclophosphamide+methotrexate+fluorouracil

CPA

Cyclophosphamide

EBCTCG

Early Breast Cancer Trialisrs’ Collaborative Group

QOL

Quality of life

This is a preview of subscription content, log in to check access.

References

  1. 1).
    Rossi A, Bonadonna G, Valagussa P,et al: Multimodal treatment in operable breast cancer; Five- year results of the CMF programme.Br Med J 282: 1427–1431, 1981.Google Scholar
  2. 2).
    Yoshimoto M, Kasumi F, Watanabe S,et al: Ten- year follow-up mitomycin C single agent adjuvant chemotherapy for breast cancer. In: Taguchi T, Andrysek O eds, New Trends in Cancer Chemotherapy with Mitomycin C, Excerpta Medica, Tokyo, pp58–67, 1987.Google Scholar
  3. 3).
    Konda C, Niitani H, Sakauchi N,et al: Chemotherapy of cancer with oral administration of N1-(2-furanidil)- 5-fluorouracil [FT-207].Jpn J Cancer Clin 19:495- 499, 1973 (in Japanese with English summary).Google Scholar
  4. 4).
    Ansfield FJ, Kallas GJ, Singson JP: Phase III studies of oral tegafur (Futraful).J Clin Oncol 1:107–110, 1983.PubMedGoogle Scholar
  5. 5).
    Adachi I: Clinical studies on the treatment of the patients with advanced breast cancer.Jpn J Cancer Chemother 21:72–78, 1981 (in Japanese with English summary).Google Scholar
  6. 6).
    Wada T, Koyama H, Nishizawa Y,et al: Chemoendocrine therapy for advanced breast cancer; A combined treatment with tamoxifen and FT-207.J Jpn Soc Cancer Ther 16:51–55, 1981 (in Japanese with English summary).Google Scholar
  7. 7).
    Abe O: The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer; Metaanalysis of the first collaborative studies of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETBC).Breast Cancer 1:1–9, 1994.CrossRefGoogle Scholar
  8. 8).
    Goldhirsch A: Meeting highlights; International panel on the treatment of primary breast cancer.JNCI 87: 1441–1445, 1995.PubMedCrossRefGoogle Scholar
  9. 9).
    Early Breast Cancer Trialists’ Collaborative Group: Treatment of Early Breast Cancer, Vol 1; Worldwide Evidence 1985–1990. Oxford University Press, Oxford, pp12–19, 1990.Google Scholar
  10. 10).
    Sakamoto G: Characteristics and future prospect of breast cancer in Japan.Jpn J Breast Cancer 2:327–338, 1987 (in Japanese with English summary).Google Scholar
  11. 11).
    Baum M: Prospects for the future in the management of carcinoma of the breast; The biological fall out from clinical trials. In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp321–329, 1984.Google Scholar
  12. 12).
    Tormy DC, Taylor SG, Kalish LA,et al: Adjuvant systemic therapy in premenopausal (CMF, CMFP, CMFPT) and postmenopausal (observation, CMFP, CMFPT) women with node positive breast cancer. In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp359- 368, 1984.Google Scholar
  13. 13).
    Fisher B: Treatment of primary breast cancer with L- PAM/5-FU and tamoxifen; An interim report.Breast Cancer Res Treat 3(Suppl 1):7–17, 1983.CrossRefGoogle Scholar
  14. 14).
    Palshof T, Carstensen B, Mouridsen HT,et al. Reviews on Endocrine-Related Cancer 17(Suppl):43- 50, 1985.Google Scholar
  15. 15).
    Wallgren A, Baral E, Carstensen J,et al: Should adjuvant tamoxifen be given for several years in breast cancer? In: Jones SE, Salmon SE eds, Adjuvant Therapy of Cancer IV, Groune & Stratton Inc, Orlando, pp331–337, 1984.Google Scholar
  16. 16).
    Patterson JS, Battersby LA, Edwards DG: Review of the clinical pharmacology and international experience with tamoxifen in advanced breast cancer. In: Lacobelli S, {eaet al} eds, The Role of Tamoxifen in Breast Cancer, Raven Press, ppl7–29, 1982.Google Scholar
  17. 17).
    Margreiter R, Wiegele J: Tamoxifen (Nolvadex) for premenopausal patients with advanced breast cancer.Breast Cancer Res Treat 4:45–48, 1984.PubMedCrossRefGoogle Scholar
  18. 18).
    Tancini G, Bonadonna G, Valagussa P,et al: Adjuvant CMF in breast cancer; Comparative 5-year results of 12 versus 6 cycles.J Clin Oncol 1:2–10, 1983.PubMedGoogle Scholar
  19. 19).
    Smalley RV, Bartolucci AA, Moore M,et al: Southeastern Cancer Study Group: Breast cancer studies 1972–1982.Int J Radiat Oncol Biol Phys 9:1867–1874, 1983.PubMedGoogle Scholar
  20. 20).
    Brincker H, Mouridsen HT, Andersen KW: Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal woman with stage II breast cancer.Breast Cancer Res Treat 3:91–95, 1983.PubMedCrossRefGoogle Scholar
  21. 21).
    Howell A, Bush H, George WD,et al: Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.Lancet 2:307–311, 1984.PubMedCrossRefGoogle Scholar
  22. 22).
    Nissen-Meyer R, Host H, Kjellgren K,et al: Scandinavian trials with short postoperative course versus a 12-cycle course.Recent Results Cancer Res 96:48- 54, 1984.PubMedGoogle Scholar
  23. 23).
    Tormy DC, Weinberg VE, Holland JF,et al: A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.J Clin Oncol 1:138–145, 1983.Google Scholar
  24. 24).
    Izuo M: Clinicopathological features of recurrent breast cancer.Jpn J Cancer Chem 12(Part I):412–420, 1985 (in Japanese with English summary).Google Scholar
  25. 25).
    Buyse M: Potential and pitfalls of randomized clinical trials in cancer research.Cancer Surv 8:91–105, 1989.PubMedGoogle Scholar
  26. 26).
    Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy.Lancet 339:1–15, 71-85, 1992.Google Scholar
  27. 27).
    Nomura Y, Tominaga T, Adachi I,et al: Clinical evaluation of cyclophosphamide, methotrexate and 5- fluorouracil (CMF) on advanced and recurrent breast cancer.Jpn J Cancer Chemother 21:1949–1956, 1994 (in Japanese with English summary).Google Scholar
  28. 28).
    Tormy C: Adjuvant systemic therapy in postoperative node-positive patients with breast carcinoma; The GALGB trial and ECOG premenopausal trial.Recent Results Cancer Res 96:153–165, 1984.Google Scholar
  29. 29).
    Yasumura T, Oka T, Honjo H: Menstrual abnormality in breast cancer patients receiving adjuvant endocrino-chemotherapy.Jpn J Cancer Chemother 15:2947- 2952, 1988 (in Japanese with English summary).Google Scholar

Copyright information

© The Japanese Breast Cancer Society 1997

Authors and Affiliations

  • Minoru Yoshida
    • 1
  • Osahiko Abe
    • 2
  • Junichi Uchino
    • 3
  • Kaneo Kikuchi
    • 4
  • Rikiya Abe
    • 5
  • Kohji Enomoto
    • 6
  • Takeshi Tominaga
    • 7
  • Atsuo Fukami
    • 8
  • Keizo Sugimachi
    • 9
  • Yasuo Nomura
    • 10
  • Takao Hattori
    • 11
  • Nobuya Ogawa
    • 12
  1. 1.Aichi Cancer Center Hospital, Chief Investigator of the Chubu RegionNagoyaJapan
  2. 2.St. Luke’s International Hospital, Chairman of ACETBC and Chief Investigator of the Kanto RegionJapan
  3. 3.The First Department of SurgeryHokkaido University School of Medicine, Chief Investigator of the Hokkaido RegionJapan
  4. 4.National Sendai Hospital, Chief Investigator of the Tohoku RegionJapan
  5. 5.The Second Department of SurgeryFukushima Medical College, Administrator of the Tohoku RegionJapan
  6. 6.Department of SurgerySchool of Medicine, Keio University, Deputy Investigator of Organizing and Steering Committee of the Kanto RegionJapan
  7. 7.Tokyo Metropolitan Komagome Hospital, Chairman of Organizing and Steering Committee of the Kanto RegionJapan
  8. 8.Kameda General Hospital, Investigator of Organizing Committee and Steering Committee of the Kanto RegionJapan
  9. 9.The Second Department of SurgeryFaculty of Medicine, Kyushu University, Co-chief Investigator of the Nishinihon RegionJapan
  10. 10.Department of Breast SurgeryNational Kyushu Cancer Center Hospital, Co-chief Investigator of the Nishinihon RegionJapan
  11. 11.Hiroshima University, Former Chief Investigator of the Nishinihon RegionJapan
  12. 12.Ehime University, ControllerJapan

Personalised recommendations